Interleukin 18

Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Toxicity, Half-life, Patient, Tumor microenvironment, Observation, Interleukin 18, AACR, Neoplasm, Cancer, Cytokine, Immune system, IL-12, Vaccine

WALTHAM, Mass and DUBLIN, Ireland, April 09, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today shared poster presentations with pre-clinical data from its Interleukin-18 (IL-18) and IL-12 programs at the American Association for Cancer Research (AACR) annual meeting taking place April 5-10 in San Diego, California. This is the first time Mural has shared findings from either program. The details for the presentations are as follows, and both posters are available at https://www.muraloncology.com/publications/.

Key Points: 
  • Mural’s protein engineering approach is twofold: first, it introduces mutations to IL-18 that are designed to minimally impact the structure while eliminating binding to IL-18BP.
  • The optimal balance of potency and pharmacokinetic enhancement is still being determined to nominate a lead IL-18 development candidate.
  • We show that resistance to IL-18BP combined with the drug’s extended half-life leads to a durable immunological effect in preclinical models.
  • “We believe that by self-assembling the split IL-12 subunits within the tumor microenvironments, we can circumvent native IL-12’s severe toxicities without compromising its efficacy.

Interleukin-18 (IL-18) Inhibitor Market Research Report 2024: Insight into Pipeline Landscape Featuring AB2 Bio, Simcha Therapeutics, GSK, Novartis, Olatec Therapeutics, Compugen, Lassen Therapeutics - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 5, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, NDA, Interleukin 18, Pharmaceutical industry

In the rapidly advancing field of medical research, a new in-depth analysis titled "Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2024" provides a detailed overview of the global pipeline landscape for Interleukin-18 (IL-18) Inhibitor therapies.

Key Points: 
  • In the rapidly advancing field of medical research, a new in-depth analysis titled "Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2024" provides a detailed overview of the global pipeline landscape for Interleukin-18 (IL-18) Inhibitor therapies.
  • This report encompasses critical data on more than four companies and over four pipeline drugs in various stages of development, from clinical trials to preclinical research.
  • The Interleukin-18 (IL-18) Inhibitor sector is undergoing significant development with companies and academics diligently analysing challenges and exploring opportunities that could influence R&D dynamics.
  • The report extends its coverage globally, thereby providing a holistic view of the Interleukin-18 (IL-18) Inhibitor pipeline across the world.

Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, May 5, 2022
CAR, COVID-19, Intrinsic termination, Forward-looking statement, Private Securities Litigation Reform Act, Euronext, Lead, Eld, IND, Interleukin 18, LLC, GLOBE, RNA, Company, Food, Safety, Research, U.S. Securities and Exchange Commission, Mont-Saint-Guibert, Patient, Wallonia, Fatality, Program, Cancer, Annual report, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Uncertainty, Lymphatic system, NKG2D, Head, SA, SEC, Risk, Vaccine, Pharmaceutical industry

The first quarter of 2022 brought us both challenges and opportunities that we are facing head-on.

Key Points: 
  • The first quarter of 2022 brought us both challenges and opportunities that we are facing head-on.
  • Enrollment in the eLD cohorts of the IMMUNICY-1 trial continues with additional data expected from the program in the second half of 2022.
  • Net cash burn during the first quarter of 2022 amounted to 9.4 million ($10.5 million), in line with expectations.
  • Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY.

Celyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highlights KEYNOTE-B79 Clinical Trial Design at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Retrieved on: 
Friday, November 12, 2021
MSD, Molecule, Euronext, Safety, SITC, Cancer, Lymphatic system, Private Securities Litigation Reform Act, Intrinsic termination, Clinical trial, Method, Wallonia, Merck, RNA, Mont-Saint-Guibert, Society, Pembrolizumab, COVID-19, CAR, Western literature, SA, Annual report, Forward-looking statement, TIM, Â, Society for Immunotherapy of Cancer, Annual general meeting, Company, GLOBE, CET, Merck Sharp & Dohme Federal Credit Union, U.S. Securities and Exchange Commission, SEC, Interleukin 18, Immunotherapy, DNA, Poster, Patient, Risk, Uncertainty, Merck & Co., NKG2D, FOLFOX, Pharmaceutical industry, Vaccine

We believe our CAR T cells are the only allogeneic CAR T cells currently in human clinical trials that avoid generating double-strand DNA breaks.

Key Points: 
  • We believe our CAR T cells are the only allogeneic CAR T cells currently in human clinical trials that avoid generating double-strand DNA breaks.
  • We believe that KEYNOTE-B79 will be the first clinical trial to evaluate an allogeneic CAR T with an anti-PD-1 therapy in solid tumors.
  • We look forward to initiating the study in the coming weeks and providing clinical updates to the CYAD-101 program in 2022.
  • These data support the ongoing development of the Companys shRNA-based allogeneic, IL-18-armored CAR T candidate CYAD-203 as well as future allogeneic IL-18-armored CAR T candidates.

Celyad Oncology Announces Third Quarter 2021 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, November 10, 2021
MSD, AML, Cancer, MSS, COVID-19, SA, University, Uncertainty, Risk, MICA, Safety, Intrinsic termination, Technology, Cyclophosphamide, Research, Forward-looking statement, TIM, Annual general meeting, GLOBE, PMMR 62, Horizon Discovery, Patient, CAR, Merck & Co., GPC3, BCMA, Lymphatic system, Private Securities Litigation Reform Act, Drug discovery, Society, Pembrolizumab, Glypican 3, LLC, U.S. Securities and Exchange Commission, SEC, Immunotherapy, NKG2D, FOLFOX, Euronext, SITC, Graft-versus-host disease, Wallonia, Merck, RNA, ASH, Mont-Saint-Guibert, TCR, MDS, MICB, Annual report, Society for Immunotherapy of Cancer, Company, Development, Interleukin 18, Investigational New Drug, Pharmaceutical industry, Vaccine, Animal, Medical device

MONT-SAINT-GUIBERT, Belgium, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the Company), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced an update on its financial results and recent business developments for the fiscal quarter ended September 30, 2021.

Key Points: 
  • MONT-SAINT-GUIBERT, Belgium, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the Company), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced an update on its financial results and recent business developments for the fiscal quarter ended September 30, 2021.
  • Research & Development Day held on July 20, 2021, during which the management team provided:
    Updates on the allogeneic CAR T clinical candidates CYAD-211 and CYAD-101.
  • Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY.
  • Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements.

Applied Molecular Transport Announces Publication of Preclinical Data Demonstrating Potential of Novel Oral IL-10 Biologic Therapeutic (AMT-101) for Inflammatory Diseases in The Journal of Immunology

Retrieved on: 
Tuesday, November 10, 2020
Medical specialties, Branches of biology, Clinical medicine, Immunology, Interleukins, Cytokine, Transcytosis, Autoimmunity, Inflammation, Sjögren syndrome, Biological therapy for inflammatory bowel disease, Interleukin 18

IL-10 is a potent immunomodulatory cytokine with significant therapeutic potential in intestinal inflammatory diseases as well as in those associated with systemic inflammation.

Key Points: 
  • IL-10 is a potent immunomodulatory cytokine with significant therapeutic potential in intestinal inflammatory diseases as well as in those associated with systemic inflammation.
  • However, clinical utilization of IL-10 to treat inflammation and immune-dysregulation has been limited due to side effects associated with systemic administration.
  • Our technology platform is based on native, active vesicular transcytosis mechanisms to rapidly and efficiently traverse intestinal epithelial cells.
  • Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases.